Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'"

What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol.

Wellcome open research·2026

The evolution of tecovirimat resistance in an immunocompromised individual with severe mpox infection.

Diagnostic microbiology and infectious disease·2026

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

Vaccine·2026

APOL1 Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

Kidney international reports·2026

The interaction between chronic hepatitis B (CHB) and Metabolic dysfunction-associated steatotic liver disease (MASLD) in a diverse central London population.

medRxiv : the preprint server for health sciences·2026

Spike 1 protein of SARS-CoV-2 induces endothelial inflammation and vascular dysfunction through interferon ISG15-dependent mechanisms.

Cardiovascular research·2026

Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis.

Journal of hepatology·2026

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

Journal of hepatology·2026

Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis.

Journal of hepatology·2026

Temporal assessment of spatial and single-cell transcriptomes identifies CD226-NECTIN2 T cell-cholangiocyte interaction in bile duct inflammation.

Journal of hepatology·2026

Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study.

Journal of hepatology·2026

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.

Journal of hepatology·2026

Periocular surgery risk after glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes.

Orbit (Amsterdam, Netherlands)·2026

Risk prediction models for venous thromboembolism in the intensive care unit: a systematic review protocol assessing model performance, risk of bias, and clinical applicability.

Systematic reviews·2026

Effect of non-intubated spontaneous breathing video-assisted thoracoscopic surgery (NI-VATS) versus intubated general anesthesia (I-VATS) on the risk of postoperative venous thromboembolism.

Journal of cardiothoracic surgery·2026

Human papillomavirus awareness and prevention practices among patients with Mayer-Rokitansky-Küster-Hauser syndrome after neovagina reconstruction: a cross-sectional study.

BMC women's health·2026

Efficiency and productivity of Mongolian subnational public hospital systems, 2014-2023: annual DEA, global Malmquist and double-bootstrap analysis.

Cost effectiveness and resource allocation : C/E·2026

Cancer care: incidence, hospitalization and medical rehabilitation statistics for Germany from 2003 to 2016.

BMC health services research·2026

Related Experiment Videos

Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from

Related Concept Videos

What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol.

The evolution of tecovirimat resistance in an immunocompromised individual with severe mpox infection.

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

APOL1 Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

The interaction between chronic hepatitis B (CHB) and Metabolic dysfunction-associated steatotic liver disease (MASLD) in a diverse central London population.

Spike 1 protein of SARS-CoV-2 induces endothelial inflammation and vascular dysfunction through interferon ISG15-dependent mechanisms.

Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis.

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis.

Temporal assessment of spatial and single-cell transcriptomes identifies CD226-NECTIN2 T cell-cholangiocyte interaction in bile duct inflammation.

Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study.

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.

Periocular surgery risk after glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes.

Risk prediction models for venous thromboembolism in the intensive care unit: a systematic review protocol assessing model performance, risk of bias, and clinical applicability.

Effect of non-intubated spontaneous breathing video-assisted thoracoscopic surgery (NI-VATS) versus intubated general anesthesia (I-VATS) on the risk of postoperative venous thromboembolism.

Human papillomavirus awareness and prevention practices among patients with Mayer-Rokitansky-Küster-Hauser syndrome after neovagina reconstruction: a cross-sectional study.

Efficiency and productivity of Mongolian subnational public hospital systems, 2014-2023: annual DEA, global Malmquist and double-bootstrap analysis.

Cancer care: incidence, hospitalization and medical rehabilitation statistics for Germany from 2003 to 2016.

Related Experiment Videos

Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from...

Related Concept Videos

Related Articles

Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from